

Genetic Technologies

00:54 01 Aug 2017

Genetic Technologies' shares surge on launching promotional campaign

Genetic Technologies (ASX:GTG) has launched a three-month promotional campaign in conjunction with Breast Cancer Awareness Month which takes place throughout October 2017.

The company's shares were last trading 33% higher intra-day, at US\$0.008.

Genetic Technologies' lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

The test assesses both clinical risk factors and genetic markers known to be associated with non-hereditary breast cancer to determine a woman's five-year risk of developing the disease.

As part of the promotion, the BREVAGenplus test will be offered at a special reduced price of US\$199.00 compared to its standard list price of US\$349.00.

In April 2017, BREVAGenplus was repositioned from a traditional reimbursement system, through insurance providers, to a direct patient self-pay program.

The initiative was implemented to better serve healthcare providers and patients by providing a streamlined, easy to use billing and payment system.

Genetic Technologies markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres.

The company also markets to obstetricians/gynaecologists and breast cancer risk assessment specialists.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and

Price: 0.0045

Market Cap: \$14.17 m

1 Year Share Price Graph



Share Information

Code: GTG

Listing: ASX

52 week High Low
0.0112 0.00373333

Sector: Pharma & Biotech

Website: www.gtglabs.com

Company Synopsis:

Genetic Technologies (ASX:GTG) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.